ImmunityBio, Inc. (FRA:26CA)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.59B +189.1% |
| Revenue (ttm) | 96.49M +668.3% |
| Net Income | -299.29M |
| EPS | -0.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 3,738 |
| Open | 6.50 |
| Previous Close | 6.40 |
| Day's Range | 6.36 - 6.53 |
| 52-Week Range | 1.63 - 10.40 |
| Beta | n/a |
| RSI | 45.30 |
| Earnings Date | Mar 2, 2026 |
About ImmunityBio
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial numbers in USD Financial StatementsNews
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
A lawsuit has been filed against ImmunityBio. ImmunityBio investors should contact Block & Leviton to possibly recover losses from their $IBRX investment.
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
ImmunityBio Inc. (NASDAQ: IBRX) shares are down during Thursday's premarket session. Year to date, the stock has jumped over 300%.
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring C...
ImmunityBio stock price crash: buy the dip or sell the rip?
ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm's promotional tactics. Investors bai...
ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses ...
ImmunityBio Crashes On FDA Warning Over Anktiva Claims
ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad
Shares of ImmunityBio fell 20% on Tuesday after the U.S. Food and Drug Administration issued a warning letter that said a television advertisement and podcast promoting its cancer therapy were fals...
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's ...
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
ImmunityBio remains a long-term buy, with Anktiva's regulatory and global expansion driving the investment thesis. IBRX's EU commercial rollout via Accord Healthcare and new Dublin subsidiary rapidly ...
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use
The agency included Anktiva in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its...
Why Is ImmunityBio Stock Soaring On Friday?
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and ...
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
ImmunityBio Inc. (NASDAQ: IBRX) shares are trading lower on Monday.
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary disease The FDA reviewed the additio...
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a busin...
ImmunityBio Investors Rally Behind Cancer Trial Milestone
ImmunityBio Inc. (NASDAQ: IBRX) shares are up during Thursday's premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Guér...
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (...
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio Inc. (NASDAQ: IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth.
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
Source: Benzinga
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive...
ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Monday following the company's announcement of significant revenue growth.
Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More
The Undercovered Dozen series spotlights 12 less-covered stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between Feb. 13 and Feb. 19, offering fresh ...
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approxi...